Search
BCc1
go.drugbank.com/drugs/DB16504ExperimentalBCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies.
Isoxsuprine
go.drugbank.com/drugs/DB08941ApprovedWithdrawnIts vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.
Befunolol
go.drugbank.com/drugs/DB09013ExperimentalBefunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.
CK0802
go.drugbank.com/drugs/DB15866InvestigationalCK0802 is an off-the-shelf product composed of allogeneic umbilical cord blood derived regulatory T-cells (T-Reg cells), which can be used intravenously and without HLA matching. … [L16358] On the surface of these T-Reg cells, T-cell lung homing markers are expressed.
Avdoralimab
go.drugbank.com/drugs/DB16392InvestigationalAvdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).
Carmegliptin
go.drugbank.com/drugs/DB12268InvestigationalCarmegliptin has been used in trials studying the treatment of Diabetes Mellitus Type 2.
Categories: DPP-IV InhibitorsFasedienol
go.drugbank.com/drugs/DB04968InvestigationalIt is a member of a new family of pharmaceutical compounds called vomeropherins. … PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder).
Acridine Carboxamide
go.drugbank.com/drugs/DB11880InvestigationalAcridine Carboxamide has been used in trials studying the treatment of Lung Cancer and Brain and Central Nervous System Tumors.
Synonyms: 4-ACRIDINECARBOXAMIDE, N-(2-(DIMETHYLAMINO)ETHYL)-, N-(2-(DIMETHYLAMINO)ETHYL)ACRIDINE-4-CARBOXAMIDECategories: Topoisomerase II InhibitorsPucotenlimab
go.drugbank.com/drugs/DB17552ApprovedInvestigational[A257296] It is being investigated in other cancers. … Pucotenlimab is a recombinant humanized anti-PD-1 monoclonal antibody. It received its first global approval in China in July 2022 for the treatment of solid tumours.